- Home
- DNA vs FULC Comparison
DNA vs FULC Comparison
Compare DNA & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNA
- FULC
- Stock Information
- Founded
- DNA 2008
- FULC 2015
- Country
- DNA United States
- FULC United States
- Employees
- DNA N/A
- FULC N/A
- Industry
- DNA Biotechnology: Biological Products (No Diagnostic Substances)
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- DNA Health Care
- FULC Health Care
- Exchange
- DNA Nasdaq
- FULC Nasdaq
- Market Cap
- DNA 529.8M
- FULC 469.0M
- IPO Year
- DNA N/A
- FULC 2019
- Fundamental
- Price
- DNA $8.01
- FULC $8.56
- Analyst Decision
- DNA Strong Sell
- FULC Buy
- Analyst Count
- DNA 1
- FULC 7
- Target Price
- DNA $9.00
- FULC $10.43
- AVG Volume (30 Days)
- DNA 1.3M
- FULC 694.7K
- Earning Date
- DNA 11-06-2025
- FULC 10-29-2025
- Dividend Yield
- DNA N/A
- FULC N/A
- EPS Growth
- DNA N/A
- FULC N/A
- EPS
- DNA N/A
- FULC N/A
- Revenue
- DNA $180,606,000.00
- FULC N/A
- Revenue This Year
- DNA N/A
- FULC N/A
- Revenue Next Year
- DNA $14.41
- FULC N/A
- P/E Ratio
- DNA N/A
- FULC N/A
- Revenue Growth
- DNA N/A
- FULC 2752.05
- 52 Week Low
- DNA $5.00
- FULC $2.32
- 52 Week High
- DNA $17.58
- FULC $10.11
- Technical
- Relative Strength Index (RSI)
- DNA 27.83
- FULC 50.94
- Support Level
- DNA $8.27
- FULC $7.51
- Resistance Level
- DNA $13.18
- FULC $9.05
- Average True Range (ATR)
- DNA 0.74
- FULC 0.79
- MACD
- DNA -0.47
- FULC -0.04
- Stochastic Oscillator
- DNA 6.46
- FULC 48.76
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.